February 23, 2023

Alger Capital Appreciation Fund et al v. Biomarin Pharmaceutical Inc et al

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. February 24, 2023

    BioMarin Hid 'Revolutionary' Drug's Troubles, Investor Says

    California-based BioMarin Pharmaceutical Inc. and two of its executives face an investor suit accusing them of failing to disclose troubles facing its "revolutionary" Hemophilia A gene therapy Valrox during its testing and approval process, while at the same time selling off "uncharacteristically" large amounts of BioMarin stock at artificially inflated prices.


Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!